MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
KLOW Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
KLOW is a compounded multi-peptide longevity blend that combines four short peptides studied for tissue repair, wound healing, and systemic regeneration: GHK-Cu (copper tripeptide-1), KPV (the C-terminal tripeptide of alpha-MSH), BPC-157 (a partial sequence of body protection compound from human gastric juice), and TB-500 (the active fragment of thymosin beta-4). Each component targets a different node of the repair response: GHK-Cu modulates copper-dependent transcription of collagen and antioxidant genes, KPV exerts anti-inflammatory effects via melanocortin signaling and direct inhibition of NF-kB, BPC-157 promotes angiogenesis and tendon-ligament healing (PMID: 17396290), and TB-500 supports actin sequestration, cell migration, and microvascular regeneration in injured tissue (PMID: 22085836). Researchers study KLOW as a combined repair stack rather than a single-mechanism agent, principally for orthopedic recovery, post-surgical healing, and age-associated decline in connective tissue regenerative capacity.
Reconstitute: Add 3 mL bacteriostatic water → 26.7 mg/mL concentration.
Easy measuring: At 26.7 mg/mL, 1 unit = 0.01 mL = 0.267 mg (267 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Half-life: Component half-lives vary: GHK-Cu and KPV clear within roughly 1-2 hours, BPC-157 has plasma exposure of several hours, and TB-500 gives prolonged tissue exposure. The blend is typically dosed once daily.
Route: Subcutaneous injection is the standard research route for the combined formulation; individual components have been studied via intramuscular, topical (GHK-Cu), and oral (BPC-157) routes.
Status: Not FDA, EMA, or MHRA approved as a finished combination product; each component is an unapproved research peptide. KLOW is a compounded blend obtained through research-chemical suppliers and is not a registered pharmaceutical.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
Interactive KLOW Syringe Calculator
Currently visualizing the 80 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 80mg dry powder in 3mL water yields 26.67 mg/mL. To evaluate a 250mcg dose, pull to 0.9 units (1 syringe ticks).
U-100 Syringe Representation
0.9 Units (1 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (per component) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 80 mg vial.
Peptide Vials (KLOW, 80 mg each):
- check8 weeks ≈ 3 vials
- check12 weeks ≈ 4 vials
- check16 weeks ≈ 5 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- check8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- check12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- check16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100-count boxes
- check12 weeks: 168 swabs → recommend 2 × 100-count boxes
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
KLOW is a compound research-chemical formulation rather than a regulated pharmaceutical product, designed to combine four peptides with complementary mechanisms in regenerative and anti-inflammatory biology. Each constituent contributes a distinct pharmacology. GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a copper-binding tripeptide originally isolated from human plasma by Loren Pickart in 1973. The peptide and its copper complex stimulate collagen and glycosaminoglycan synthesis in dermal fibroblasts, activate angiogenesis via VEGF and other pathways, increase expression of antioxidant enzymes, and modulate hundreds of genes associated with tissue remodeling and wound healing [1]. KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH) and retains its anti-inflammatory activity without melanotropic effects. Catania, Lipton, and colleagues established that KPV downregulates pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), suppresses NF-kB activation, and modulates innate immune cells in gut and epithelial tissues, with documented efficacy in colitis and inflammatory dermatologic models [2]. BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid sequence derived from a protective peptide isolated from human gastric juice. Sikiric and colleagues have published extensively on BPC-157's gastroprotective, soft-tissue repair, and anti-inflammatory activities, with effects mediated through nitric oxide signaling, growth factor receptor upregulation, and cytokine balance restoration in rodent models of tendon, ligament, muscle, and gastrointestinal injury [3][4]. TB-500 (thymosin beta-4 fragment 17-23 acetylated; the actual commercial product is a synthetic version of the active region of thymosin beta-4 rather than the full 43-residue protein) supports actin sequestration and remodeling, promotes endothelial cell migration and angiogenesis through integrin-linked pathways, and reduces inflammation in cardiac and skeletal muscle injury models [5]. The biological rationale for the KLOW blend is that these four peptides act through largely non-overlapping mechanisms, so their effects on collagen synthesis (GHK-Cu), inflammation (KPV and BPC-157), angiogenesis (GHK-Cu, BPC-157, TB-500), and matrix remodeling (TB-500, GHK-Cu) may converge to support faster and more complete tissue repair than any single component. Empirical evidence for this combinatorial benefit in controlled trials is absent; the KLOW formulation is a research-community construct rather than a regulator-validated combination product. Administration is parenteral: subcutaneous injection is the most common route, with the lyophilized 80 mg blend reconstituted in 2–5 mL of bacteriostatic water to allow dosing of 500–1000 mcg per injection (corresponding to roughly 300–600 mcg GHK-Cu, 60–120 mcg KPV, and 60–120 mcg each of BPC-157 and TB-500 per dose). Typical research protocols administer the blend daily or twice daily for 4–6 weeks. None of the four constituent peptides have FDA approval, and several (BPC-157, TB-500) have been explicitly added to the World Anti-Doping Agency Prohibited List and have been the subject of FDA warning communications regarding compounding.
Clinical Trial Efficacy Highlights
- starPickart and colleagues established that GHK-Cu stimulates collagen synthesis, supports angiogenesis, and accelerates wound healing in animal and human dermal models, with the tripeptide-copper complex acting as a master regulator of tissue remodeling gene programs [1].
- starCatania, Lipton and colleagues demonstrated that KPV, the C-terminal tripeptide of alpha-MSH, suppresses pro-inflammatory cytokines and NF-kB signaling in epithelial and immune cells, with anti-inflammatory efficacy in animal models of colitis without melanotropic effects [2].
- starSikiric and colleagues showed in over 100 published studies that BPC-157 accelerates healing of tendon, ligament, muscle, and gastrointestinal injuries in rodent models at parenteral doses of 10 mcg/kg, with mechanisms including nitric oxide signaling, VEGF upregulation, and cytokine modulation [3][4].
- starGoldstein and colleagues demonstrated that thymosin beta-4 and its active fragments (the basis of TB-500) promote cell migration, angiogenesis, and tissue repair across multiple injury models including cardiac infarction, dermal wounds, and corneal injury [5].
- starPickart and Margolina reviewed 40+ years of GHK-Cu research showing reduced markers of cellular senescence in fibroblast cultures, restored gene expression patterns characteristic of younger cells, and improved skin barrier function in clinical cosmetic trials [6].
- starBPC-157 has shown efficacy in models of brain injury, spinal cord injury, and inflammatory bowel disease at parenteral microgram doses, supporting broad systemic regenerative and anti-inflammatory activity beyond local tissue repair.
- starTB-500 has been investigated in equine sport medicine and in preclinical models of myocardial infarction, where it reduces infarct size, supports cardiac stem cell recruitment, and improves ventricular function after ischemic injury.
- starNo randomized controlled trials of the KLOW combination product itself exist in humans; all efficacy claims rest on individual-constituent preclinical data and uncontrolled clinical observation in research-community use.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningKLOW is administered as a parenteral peptide blend; injection-site reactions (redness, induration, brief discomfort) are the most common adverse effect, generally mild and self-limited.
- warningBPC-157 carries an FDA warning communication regarding compounding and is on the WADA Prohibited List; theoretical concerns include angiogenic stimulation in tissues with occult malignancy, though no clinical evidence of tumor promotion exists.
- warningTB-500 is similarly on the WADA Prohibited List and shares angiogenic stimulation concerns; theoretical risks in patients with active or recent malignancy warrant caution.
- warningGHK-Cu can produce transient flushing, mild warmth, or histaminergic symptoms with rapid subcutaneous administration; this is generally tolerable and resolves within minutes.
- warningKPV is generally well tolerated; rare hypersensitivity reactions have been described with peptide preparations and warrant discontinuation if they occur.
- warningCombination dosing has the potential for additive immunomodulatory effects; theoretical concerns about combined anti-inflammatory activity in patients with active infection have not been clinically characterized.
- warningDrug-drug interaction data are absent for the blend; theoretical interactions with anticoagulants (via angiogenic stimulation) or immunomodulators are unstudied.
- warningReproductive, pregnancy, and lactation safety of KLOW and its constituents is entirely unstudied; use during these periods is not recommended.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical KLOW dosage?expand_more
Typical research dosing is 500–1000 mcg of the blend subcutaneously per day across 4–6 week cycles. The standard 80 mg vial reconstituted in 2–5 mL bacteriostatic water provides 16–40 mg/mL, allowing flexible dose volumes. Twice-daily dosing is sometimes used in injury recovery protocols.
How is KLOW administered?expand_more
KLOW is administered by subcutaneous injection, typically into abdominal subcutaneous tissue or near the area of intended tissue repair. Intramuscular injection is sometimes used. The lyophilized 80 mg blend is reconstituted with bacteriostatic water and stored refrigerated, with the reconstituted solution stable for several weeks.
Can KLOW be stacked?expand_more
KLOW is itself a stack of four peptides. Further combination with other peptides (CJC-1295, ipamorelin, GHK-Cu solo) is described in research-community protocols. Combination with NSAIDs or corticosteroids may blunt the anti-inflammatory effect of the blend's constituents.
What are the side effects of KLOW?expand_more
Most common are injection-site irritation, occasional flushing or warmth from GHK-Cu, and rare hypersensitivity. Theoretical risks include angiogenic stimulation in occult malignancy (BPC-157, TB-500). Long-term safety has not been established and several constituents carry FDA compounding warnings.
Is KLOW FDA approved?expand_more
No. KLOW is not FDA approved as a combination product, and none of its four constituent peptides (GHK-Cu, KPV, BPC-157, TB-500) are FDA approved as pharmaceuticals. BPC-157 and TB-500 are on the WADA Prohibited List; FDA has issued compounding warnings regarding these peptides.
Academic References & Study Citations
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. View Scientific Paper →
Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. ScientificWorldJournal. 2010;10:1840-53. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. View Scientific Paper →
Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. View Scientific Paper →
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. View Scientific Paper →
Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. View Scientific Paper →
Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and cyclooxygenase-2. Digestion. 2002;65(2):69-77. View Scientific Paper →
Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-89. View Scientific Paper →
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. View Scientific Paper →
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. View Scientific Paper →